About Seres Therapeutics
Seres Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2010 by David Berry. Microbiome therapeutics are developed to address diverse diseases. Seres Therapeutics has raised $257.13 million across 9 funding rounds from investors including ARE, Flagship Pioneering and Nestlé Health Science. The company has 103 employees. Seres Therapeutics offers products and services including Live Biotherapeutics and GoodNature Program. Its focus areas include Life Sciences, Microbiome Therapeutics, Probiotics and Clinical Genomics. Its legal entity is SERES THERAPEUTICS, INC. Its competitors include Biogen, Denali Therapeutics and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Seres Therapeutics was founded in 2010 and is based in Cambridge, United States. Operations center on the biotechnology sector, where microbiome-based therapeutics are created for treating conditions such as C. difficile infection, antibiotic-resistant infections, graft-versus-host disease, and ulcerative colitis. The pipeline includes candidates like SER-109, SER-155, and SER-287, with development focused on clinical advancement and therapeutic applications.
- Headquarters Cambridge, United States
- Employees 103
- Founders David Berry
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website serestherapeutics.com
- Social LinkedIn X Facebook
- Legal Name Seres Therapeutics, Inc.
- Annual Revenue$789 K (USD)as on Dec 31, 2025
- Net Profit$5.7 M (USD)as on Dec 31, 2025
- EBITDA-$89.84 M (USD)13.07as on Dec 31, 2025
- Total Equity Funding$257.13M (USD)
in 9 rounds
- InvestorsARE
& 6 more
- Employee Count103
Products & Services of Seres Therapeutics
Seres Therapeutics offers a comprehensive portfolio of products and services, including Live Biotherapeutics and GoodNature Program.
Treats bacterial infections and GI diseases through innovative biotherapeutics.
Facilitates stool donations for biotherapeutics research and development.
Funding Insights of Seres Therapeutics
Seres Therapeutics has successfully raised a total of $257.13M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $257.13M
- Total Rounds 9
- First Round $10.5M
(Nov 2013)
- Investors Count 7
All 9 funding rounds of Seres Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | Post-IPO | – | – | ||
| Nov 2017 | $2.5M | Grant | – | – | |
| Jan 2015 | $65M | Series D | – | – | – |
| Dec 2014 | $65M | Series D | – | Nestlé Health Science | – |
| Dec 2014 | $48M | Series C | – | – | |
| Nov 2014 | $48M | Series C | – | – | – |
| Jun 2014 | $10M | Series B | – | – | |
| Jun 2014 | $10.63M | Series B | – | Enso Ventures, Alexandria | – |
| Nov 2013 | $10.5M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Seres Therapeutics
Seres Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Flagship Pioneering and Nestlé Health Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| ludicrousventures.com | ||||
| ensoventures.com | ||||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Healthcare startups are accelerated by Mayo Clinic Business Accelerator. | mcbusaccel.com | Rochester, United States | ||
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States | |
Nutritional dietary supplements are provided for health and wellness needs. | 2011 | nestlehealthscience.com | Epalinges, Switzerland | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Seres Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Seres Therapeutics
83 people are tracked at Seres Therapeutics (41 in leadership, 12 in board & advisors, 30 in team); the tracked headcount is 103.
| Name | Role | Group |
|---|---|---|
David Berry | Founder | Leadership |
Matthew Henn | EVP, Chief Scientific Officer | Leadership |
Terri Young | EVP, Chief Commercial & Strategy Officer | Leadership |
Thomas J. Desrosier | EVP, Chief Legal Officer & Secretary | Leadership |
Marella Thorell | EVP & CFO | Leadership |
Michael Philbrook | Senior Director Of Formulations | Leadership |
Jill Colabella | Executive Director, Clinical Operations | Leadership |
Oonagh MacVeigh | Director, Clinical Supply | Leadership |
Sherry Weigand | Svp, Head Of Clinical Science | Leadership |
Ann Kurowski | Sr. Vice President Regulatory Affairs | Leadership |
Tori Mokrisky | Associate Director, Total Rewards & People Operations | Leadership |
Eric Shaff | President & CEO | Leadership |
Kimberly McGrath | Executive Director Clinical Data Management | Leadership |
Asuncion Martinez | Senior Director Of Microbiology And Functional Screening | Leadership |
Geoffrey von Maltzahn | Co Founder CTO 2010 2012 | Leadership |
Chris McChalicher | Svp, Head Of CMC And Quality At Seres Therapeutics | Leadership |
Sean Sykes | Vice President, Bioinformatics & IT | Leadership |
Alyssa D'Eramo | Vice President, Corporate Controller | Leadership |
Emily Walsh | Director Research Technologies | Leadership |
Dennis M Walling | Vice President, Clinical Development, And Head Of Clinical Research | Leadership |
63 more people are available in the full profile.
Complete people profiles for Seres Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Seres Therapeutics
Seres Therapeutics is a publicly listed company on the NASDAQ with ticker symbol MCRB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Jun 2015
- Listed onNASDAQ: MCRB
- Listed entitySeres Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS81750R2013
- Share price$2.53 (-5.6% on the day) · 2026-10-13
- Market capitalisation$25.2M
- Price to earnings28.3
- EPS (diluted, trailing year)$-2.28
- Volume (last session)44,061
Financials of Seres Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $789,000 | $5.7M | -$89.8M |
| 2024 | -$146.6M | -$103.3M | |
| 2023 | -$113.7M | -$180.0M | |
| 2022 | $7.1M | -$250.2M | -$233.6M |
| 2021 | $144.9M | -$65.6M | -$57.0M |
Detailed financial statements for Seres Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Seres Therapeutics
4 dated milestones of Seres Therapeutics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Seres Therapeutics is founded.
- Funding First funding round of $10.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Seres Therapeutics
Seres Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Denali Therapeutics and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Seres Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Seres Therapeutics
The website of Seres Therapeutics (serestherapeutics.com) receives about 5.8K visits a month and ranks #3,508,074 among all websites worldwide, #4,548 in Biotechnology and Pharmaceuticals.
- Monthly visits5.8K
▲ 3.4% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,508,074
among all websites
- Category rank#4,548
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.7
- Average visit19 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Seres Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicaltrialsarena.com | 100% | #257,942 | View details |
Top companies in Microbiome Therapeutics
3 companies that operate in the same segment as Seres Therapeutics (Microbiome Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | 55 | ||
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | 12 | ||
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Seres Therapeutics
Complete news archive for Seres Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seres Therapeutics
Seres Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Seres Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Seres Therapeutics is a funded company, having raised a total of $257.13M across 9 funding rounds to date. The company's 1st funding round was a Series A of $10.5M, raised on Nov 2013.
Seres Therapeutics has 103 employees.
Annual revenue of Seres Therapeutics is $789K as on Dec 31, 2025.
Seres Therapeutics was founded in 2010 and is based in Cambridge, United States. Operations center on the biotechnology sector, where microbiome-based therapeutics are created for treating conditions such as C. difficile infection, antibiotic-resistant infections, graft-versus-host disease, and ulcerative colitis. The pipeline includes candidates like SER-109, SER-155, and SER-287, with development focused on clinical advancement and therapeutic applications.
Seres Therapeutics's top competitors include Denali Therapeutics, Biogen and MiRagen.
Seres Therapeutics offers Live Biotherapeutics and GoodNature Program.
Yes, Seres Therapeutics is publicly traded on NASDAQ under the ticker symbol MCRB.
Seres Therapeutics has 7 investors. Key investors include ARE, Flagship Pioneering, Nestlé Health Science, CARB-X, and Ludicrous Ventures.
Seres Therapeutics operates through Seres Therapeutics, Inc..